Fig1.jpg (Fig1)
The text provides data from a study on the effectiveness of Atenolol and Losartan in reducing the risk of the primary endpoint, with an adjusted risk reduction of 13% and p-value of 0.021. The percentage of patients with the primary endpoint is not mentioned. The study was conducted over 66 study months.*